New Agonist- and Antagonist-Based Treatment Approaches for Advanced Prostate Cancer

Xu, Yuan; Jiang, Yonghua; Wu, Bin

doi:10.1177/147323001204000401

Cited by 9 publications

(6 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increasing interest in peptide based therapeutics has led to the development of many peptide databases with therapeutic properties like anticancer [ 14 ], antihypertensive [ 15 ], antimicrobial [ 16 ], blood-brain barrier [ 17 ], antiparasitic [ 18 ], hemolytic [ 19 ], quorum-sensing [ 20 ], tumor homing [ 21 ] and cell penetrating [ 22 ]. So far, peptide based drugs have been employed for many diseases and these are being investigated in clinical applications against tumors, either for imaging or therapy [ 3 , 23 – 26 ]. In general, they are attractive molecules as therapeutics because of their natural availability, ability to penetrate cells, specific target binding, and diverse modifications giving flexibility for different applications.…”

Section: Introductionmentioning

confidence: 99%

AntiAngioPred: A Server for Prediction of Anti-Angiogenic Peptides

et al. 2015

View full text Add to dashboard Cite

The process of angiogenesis is a vital step towards the formation of malignant tumors. Anti-angiogenic peptides are therefore promising candidates in the treatment of cancer. In this study, we have collected anti-angiogenic peptides from the literature and analyzed the residue preference in these peptides. Residues like Cys, Pro, Ser, Arg, Trp, Thr and Gly are preferred while Ala, Asp, Ile, Leu, Val and Phe are not preferred in these peptides. There is a positional preference of Ser, Pro, Trp and Cys in the N terminal region and Cys, Gly and Arg in the C terminal region of anti-angiogenic peptides. Motif analysis suggests the motifs “CG-G”, “TC”, “SC”, “SP-S”, etc., which are highly prominent in anti-angiogenic peptides. Based on the primary analysis, we developed prediction models using different machine learning based methods. The maximum accuracy and MCC for amino acid composition based model is 80.9% and 0.62 respectively. The performance of the models on independent dataset is also reasonable. Based on the above study, we have developed a user-friendly web server named “AntiAngioPred” for the prediction of anti-angiogenic peptides. AntiAngioPred web server is freely accessible at http://clri.res.in/subramanian/tools/antiangiopred/index.html (mirror site: http://crdd.osdd.net/raghava/antiangiopred/).

show abstract

Section: Introductionmentioning

confidence: 99%

AntiAngioPred: A Server for Prediction of Anti-Angiogenic Peptides

et al. 2015

View full text Add to dashboard Cite

show abstract

“…LHRH agonists currently used for the ADT include buserelin, leuprolide (Lupron), goserelin (Zoladex), Histrelin, and triptorelin (Trelstar). Lupron causes a prolonged decrease in the release of FSH and LH due to the continuous stimulation of the anterior pituitary leading to the desensitization of the LHRH receptor and therefore, causing the suppression of androgen synthesis [130]. Some of the drawbacks of LHRH agonists are their high costs, impotence, hot flashes and libido loss in treated patients [131].…”

Section: Lhrh Agonistsmentioning

confidence: 99%

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

Saranyutanon

Srivastava

Pai

et al. 2019

Cancers

View full text Add to dashboard Cite

Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the second leading cause of cancer-related death affecting men in the United States. Moreover, it disproportionately affects the men of African origin, who exhibit significantly greater incidence and mortality as compared to the men of European origin. Since androgens play an important role in the growth of normal prostate and prostate tumors, targeting of androgen signaling has remained a mainstay for the treatment of aggressive prostate cancer. Over the years, multiple approaches have been evaluated to effectively target the androgen signaling pathway that include direct targeting of the androgens, androgen receptor (AR), AR co-regulators or other alternate mechanisms that impact the outcome of androgen signaling. Several of these approaches are currently in clinical practice, while some are still pending further development and clinical evaluation. This remarkable progress has resulted from extensive laboratory, pre-clinical and clinical efforts, and mechanistic learnings from the therapeutic success and failures. In this review, we describe the importance of androgen signaling in prostate cancer biology and advances made over the years to effectively target this signaling pathway. We also discuss emerging data on the resistance pathways associated with the failure of various androgen signaling-targeted therapies and potential of this knowledge for translation into future therapies for prostate cancer.

show abstract

“…Consequently, there are more androgens available to interact with the AR and enhance the growth of prostate cancer. Lupron is a LHRH agonist that while initially increases the amount of FSH and LH, eventually causes a prolonged decrease in the release of FSH and LH due to continuous stimulation of the anterior pituitary—thus preventing androgen synthesis (Xu et al, ). In addition to castration, the use of Lupron and other LHRH agonists has become one of the most common androgen deprivation (ADT) therapies used in the prevention and treatment of prostate cancer (Choi and Lee, ).…”

Section: Indirectly Targeting the Armentioning

confidence: 99%

Advances in Androgen Receptor Targeted Therapy for Prostate Cancer

Ahmed

Ali

Sarkar

2013

Journal Cellular Physiology

View full text Add to dashboard Cite

Prostate Cancer (PCa) is the second leading cause of cancer death in men. Current research findings suggest that the androgen receptor (AR) and its signaling pathway contribute significantly to the progression of metastatic PCa. The AR is a ligand activated transcription factor, where androgens such as testosterone (T) and dihydroxytestosterone (DHT) act as the activating ligands. However in many metastatic PCa, the AR functions promiscuously and is constitutively active through multiple mechanisms. Inhibition of enzymes that take part in androgen synthesis or synthesizing antiandrogens that can inhibit the AR are two popular methods of impeding the androgen receptor signaling axis; however, the inhibition of androgen-independent activated AR function has not yet been fully exploited. This article focuses on the development of emerging novel agents that act at different steps along the androgen-AR signaling pathway to help improve the poor prognosis of PCa patients.

show abstract

New Agonist- and Antagonist-Based Treatment Approaches for Advanced Prostate Cancer

Cited by 9 publications

References 64 publications

AntiAngioPred: A Server for Prediction of Anti-Angiogenic Peptides

AntiAngioPred: A Server for Prediction of Anti-Angiogenic Peptides

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

Advances in Androgen Receptor Targeted Therapy for Prostate Cancer

Contact Info

Product

Resources

About